Despite all the advances in drug research and development, the human proteome remains largely untapped – of the estimated 20,000 proteins, only about 600 are currently targeted by FDA-approved drugs. That leaves a lot of opportunity on the table for Vividion Therapeutics Inc., a San Diego-based firm launching Thursday with a $50 million series A investment co-led by Arch Venture Partners and Versant Ventures.